Yu Jung Kim

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

Hyesil Seol, Hyun Ju Lee, Yoomi Choi et al. · Modern Pathology · 2012 · 333 citations · Full text

Medicine, Oncology, Pathology +16

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

Heae Surng Park, Min Hye Jang, Eun Joo Kim et al. · Modern Pathology · 2014 · 294 citations · Full text

Medicine, Genetics, Oncology +14

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Sehhoon Park, Chan‐Young Ock, Hyojin Kim et al. · Journal of Clinical Oncology · 2022 · 282 citations · Full text

Medicine, Immunology, Oncology +17

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

Jin Won Kim, Kyung Han Nam, Sang-Hoon Ahn et al. · Gastric Cancer · 2014 · 249 citations · Full text

Medicine, Immunology, Oncology +17